Propel Bio Management, LLC Avidity Biosciences, Inc. Transaction History
Propel Bio Management, LLC
- $154 Billion
- Q2 2024
A detailed history of Propel Bio Management, LLC transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Propel Bio Management, LLC holds 178,500 shares of RNA stock, worth $7.22 Million. This represents 4.73% of its overall portfolio holdings.
Number of Shares
178,500
Previous 178,500
-0.0%
Holding current value
$7.22 Million
Previous $4.56 Billion
60.07%
% of portfolio
4.73%
Previous 2.65%
Shares
1 transactions
Others Institutions Holding RNA
# of Institutions
206Shares Held
95.5MCall Options Held
171KPut Options Held
196K-
Price T Rowe Associates Inc Baltimore, MD10.9MShares$442 Million0.05% of portfolio
-
Rtw Investments, LP New York, NY8.81MShares$356 Million6.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$349 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.51MShares$263 Million3.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.94MShares$240 Million0.0% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $2.11B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...